For patients who did not meet inclusion criteria, and for each patient withdrawn from treatment after randomization, more than 1 reason could apply. Patients who withdrew their consent (1 in the midazolam group and 2 in the propofol group) denied any use of their data in the analyses.
In the MIDEX trial (midazolam vs dexmedetomidine), the median duration of mechanical ventilation was, for dexmedetomidine, 123 hours (interquartile range [IQR], 67-337 hours) and, for midazolam, 164 hours (IQR, 92-380 hours) (Gehan-Wilcoxon P = .03). The median length of stay in the intensive care unit (ICU) from randomization until the patient was medically fit for discharge was, for dexmedetomidine, 211 hours (IQR, 115-831 hours) and, for midazolam, 243 hours (IQR, 140-630 hours; Gehan-Wilcoxon P = .27). In the PRODEX trial (propofol vs dexmedetomidine), the median duration of mechanical ventilation was, for dexmedetomidine, 97 hours (IQR, 45-257 hours) and, for propofol, 118 hours (IQR, 48-327 hours) (Gehan-Wilcoxon P = .24). The median length of stay in the ICU from randomization until the patient was medically fit for discharge was, for dexmedetomidine, 164 hours (IQR, 90-480 hours) and, for propofol, 185 hours (93-520 hours; Cox's proportional hazards test P = .54). Study drugs were given for a maximum of 336 hours in both trials.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs Midazolam or Propofol for Sedation During Prolonged Mechanical Ventilation: Two Randomized Controlled Trials. JAMA. 2012;307(11):1151–1160. doi:10.1001/jama.2012.304
Author Affiliations: Department of Intensive Care Medicine, Bern University Hospital and University of Bern, Bern, Switzerland (Drs Jakob and Takala); Department of Anesthesiology and Intensive Care Medicine, Kuopio University Hospital, Kuopio, Finland (Dr Ruokonen); Adult Intensive Care Unit, St James Wing, St George's Hospital, London, United Kingdom (Dr Grounds); Orion Pharma, Espoo, Finland (Messrs Sarapohja, Garratt, and Bratty); and Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, United Kingdom (Dr Pocock).
Context Long-term sedation with midazolam or propofol in intensive care units (ICUs) has serious adverse effects. Dexmedetomidine, an α2-agonist available for ICU sedation, may reduce the duration of mechanical ventilation and enhance patient comfort.
Objective To determine the efficacy of dexmedetomidine vs midazolam or propofol (preferred usual care) in maintaining sedation; reducing duration of mechanical ventilation; and improving patients' interaction with nursing care.
Design, Setting, and Patients Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010. The MIDEX trial compared midazolam with dexmedetomidine in ICUs of 44 centers in 9 European countries; the PRODEX trial compared propofol with dexmedetomidine in 31 centers in 6 European countries and 2 centers in Russia. Included were adult ICU patients receiving mechanical ventilation who needed light to moderate sedation for more than 24 hours (midazolam, n = 251, vs dexmedetomidine, n = 249; propofol, n = 247, vs dexmedetomidine, n = 251).
Interventions Sedation with dexmedetomidine, midazolam, or propofol; daily sedation stops; and spontaneous breathing trials.
Main Outcome Measures For each trial, we tested whether dexmedetomidine was noninferior to control with respect to proportion of time at target sedation level (measured by Richmond Agitation-Sedation Scale) and superior to control with respect to duration of mechanical ventilation. Secondary end points were patients' ability to communicate pain (measured using a visual analogue scale [VAS]) and length of ICU stay. Time at target sedation was analyzed in per-protocol population (midazolam, n = 233, vs dexmedetomidine, n = 227; propofol, n = 214, vs dexmedetomidine, n = 223).
Results Dexmedetomidine/midazolam ratio in time at target sedation was 1.07 (95% CI, 0.97-1.18) and dexmedetomidine/propofol, 1.00 (95% CI, 0.92-1.08). Median duration of mechanical ventilation appeared shorter with dexmedetomidine (123 hours [IQR, 67-337]) vs midazolam (164 hours [IQR, 92-380]; P = .03) but not with dexmedetomidine (97 hours [IQR, 45-257]) vs propofol (118 hours [IQR, 48-327]; P = .24). Patients' interaction (measured using VAS) was improved with dexmedetomidine (estimated score difference vs midazolam, 19.7 [95% CI, 15.2-24.2]; P < .001; and vs propofol, 11.2 [95% CI, 6.4-15.9]; P < .001). Length of ICU and hospital stay and mortality were similar. Dexmedetomidine vs midazolam patients had more hypotension (51/247 [20.6%] vs 29/250 [11.6%]; P = .007) and bradycardia (35/247 [14.2%] vs 13/250 [5.2%]; P < .001).
Conclusions Among ICU patients receiving prolonged mechanical ventilation, dexmedetomidine was not inferior to midazolam and propofol in maintaining light to moderate sedation. Dexmedetomidine reduced duration of mechanical ventilation compared with midazolam and improved patients' ability to communicate pain compared with midazolam and propofol. More adverse effects were associated with dexmedetomidine.
Trial Registration clinicaltrials.gov Identifiers: NCT00481312, NCT00479661
Sedation in intensive care patients is assumed to reduce discomfort from care interventions, increase tolerance of mechanical ventilation, prevent accidental removal of instrumentation, and reduce metabolic demands during cardiovascular and respiratory instability.1 Long-term sedation may have serious adverse effects, such as prolonged mechanical ventilation,2 coma,3 delirium,4 delusional memories and posttraumatic stress disorder,5,6 impaired cognitive function,7 prolonged hospitalization,2,3,8,9 increased costs,2,3,8 and mortality.9 Daily sedation stops,3 sedation protocols,3,8 spontaneous breathing trials and early mobilization,9,10 or primary use of opiates without other sedation11 may help reduce these complications.
Current sedatives are problematic in long-term sedation. Benzodiazepines and propofol accumulate unpredictably.12,13 High-dose or prolonged propofol use may cause potentially fatal propofol infusion syndrome.14 Dexmedetomidine, a sedative with high α2-adrenoreceptor affinity and action in the locus ceruleus, is an alternative for sedation in intensive care units (ICUs). Dexmedetomidine may enhance patient safety and comfort in long-term sedation. It reduced the incidence of coma and delirium when compared with lorazepam15 and—in a pilot study—reduced duration of mechanical ventilation when compared with propofol or midazolam.16 A multicenter trial in predominantly medical ICU patients found earlier extubation and reduced delirium with dexmedetomidine compared with midazolam.17 However, a recent meta-analysis presented inconclusive results for the effect of dexmedetomidine on duration of mechanical ventilation and ICU stay.18 Most clinicians and centers do not consider midazolam and propofol as equivalent alternatives for long-term sedation.
We designed 2 large, parallel, randomized controlled multicenter trials to compare dexmedetomidine with either midazolam or propofol, according to the preferred usual sedation of study centers. The study designs were identical except for the usual-care control drug. We included higher doses and longer treatment than currently approved for dexmedetomidine. We assessed whether dexmedetomidine is noninferior to midazolam or propofol in maintaining mild to moderate sedation and offers benefits in terms of reduced mechanical ventilation and ICU stay and patients' ability to communicate during sedation.
These 2 phase 3, European, multicenter, randomized, double-blind studies conducted in 2007 through 2010 compared midazolam with dexmedetomidine (MIDEX trial; 44 centers in 9 European countries) and propofol with dexmedetomidine (PRODEX trial; 31 centers in 6 European countries and 2 in Russia) and were approved by the respective ethics committees (eAppendix). Written informed consent was obtained from the patient's family, a legal representative, or both. An independent data safety monitoring board had full access to the ongoing unblinded data and made regular recommendations to the sponsor and steering committee, based on the risk-benefit evaluation, regarding continuation, adjustment, or termination of the 2 trials.
The main inclusion criteria were age 18 years or older, invasive mechanical ventilation, clinical need for light to moderate sedation (target sedation Richmond Agitation-Sedation Scale [RASS] score was from 0, alert and calm, to −3, responds to verbal stimulation by movement or eye opening to voice but no eye contact19) using midazolam or propofol infusion expected to last for 24 hours or longer after randomization, and randomization within 72 hours of ICU admission and within 48 hours of starting continuous sedation.
The main exclusion criteria were acute severe neurological disorder, mean arterial pressure less than 55 mm Hg despite appropriate intravenous volume replacement and vasopressors, heart rate less than 50/min, atrioventricular-conduction grade II or III (unless pacemaker installed), and use of α2 agonists or antagonists within 24 hours prior to randomization. The most common reasons that patients were excluded were that they were not ventilated, they were expected to need less than 24 hours sedation, or they had an acute severe neurological disorder (complete list of exclusion criteria in eAppendix).
Eligible study participants were randomized 1:1 by a central interactive voice-response system funded by the sponsor to either continue their current standard care (midazolam [MIDEX trial] or propofol [PRODEX trial]) or switch to dexmedetomidine. Randomization was stratified for study center in blocks of 4. All patients and study personnel were masked to treatment allocation. Treatments were administered in a double-dummy design, with 0.9% sodium chloride as dummy for all treatments. Propofol and propofol dummy were prepared, connected, and removed by independent personnel and infused with nontransparent black syringes, infusion tubings, and connectors.
Study treatments were titrated to individual sedation targets. Depth of sedation was assessed using RASS scores,19 which range from −5 (unarousable) to +4 (combative) (eAppendix); target RASS score was determined before starting study treatment and at daily sedation stops. Assessment of RASS score was performed every 2 hours and prior to any dose of rescue therapy. Six dose levels of each study drug covered the full dose range (dexmedetomidine, 0.2-1.4 μg/kg per hour; midazolam, 0.03-0.2 mg/kg per hour; propofol, 0.3-4.0, mg/kg per hour). Study treatments were infused without loading dose at a dose matching the prerandomization dose of midazolam (MIDEX trial) or propofol (PRODEX trial) for 1 hour. Thereafter, study drugs were titrated by the patient's nurse stepwise to maintain the target RASS score (eAppendix).
Pain was treated with fentanyl boli. Rescue medication boli could be given if needed to achieve target RASS score (first-line rescue propofol in the MIDEX trial and midazolam in the PRODEX trial; further rescue medication decided by treating clinician). Need for resedation and continued ventilation was assessed after a daily sedation stop and spontaneous breathing trial. Study medication was continued up to a maximum of 14 days from randomization and stopped at the time of extubation. Patients were followed up for 45 days.
The first primary efficacy end point was the proportion of time in target sedation range (RASS score, 0 to −3) without use of rescue therapy of the total duration of study drug infusion; the other was duration of mechanical ventilation from randomization until patients were free of mechanical ventilation (including noninvasive) without reinstitution for the following 48 hours.
Secondary efficacy outcomes were length of ICU stay from randomization until medically fit for discharge and nurses' assessment of arousal, ability to cooperate with care, and ability to communicate pain16 using visual analogue scales (VAS). The follow-up visit occurred on day 45 after randomization. (Refer to the eAppendix for more prespecified end points and safety monitoring.)
The planned enrolment was 500 participants in each trial. Based on a pilot study,16 we assumed an overall 64% of time in target range of sedation without using rescue medication. A sample size of 450 in each trial gives 90% power to reject a 15% inferiority of dexmedetomidine to standard sedation using a 2-sided 95% confidence interval for the estimated ratio of dexmedetomidine to standard care.
Proportion of time within RASS target without rescue medication was analyzed in the per-protocol population to avoid bias toward noninferiority using a variance analysis model with fixed effects for treatment and country. Noninferiority margin was defined as 15%; ie, the lower 95% CI of the estimated dexmedetomidine-to-standard-care ratio of proportion of time in range must be above 0.85. Variance estimate of the ratio was calculated from the estimated covariance matrix. A sensitivity analysis using the intention-to-treat population was also performed.
The intention-to-treat population, including all randomized patients, was used for all other efficacy variables to analyze superiority. Safety was analyzed in patients who received any study drug. Length of ICU stay was until patients were judged medically fit for discharge. The primary analysis of the duration of mechanical ventilation, length of ICU stay, time to extubation, and length of hospital stay was based on a Cox proportional hazards regression model, stratified by country. The proportional hazards assumptions were only fulfilled for length of hospital stay and length of ICU stay in the propofol vs dexmedetomidine study. Use of alternative tests was predefined in the analysis plan; therefore, the Gehan-Wilcoxon test was used post hoc. Calculation of descriptive medians and interquartile ranges excluded censored cases. Results for the VAS were analyzed using analysis of covariance, adjusting for country and baseline value. (For imputation rules, see the eAppendix.) Proportional analyses for longitudinal data were based on a generalized estimating equation model with factors for treatment, time, and country.
All data are presented as median and interquartile range (IQR) unless indicated otherwise. A 2-sided significance level of .05 was used in all treatment comparisons. Proportionality assumption was tested on a .10 level. SAS statistics software version 9.1 was used.
The intention-to-treat populations included 249 and 251 patients in the dexmedetomidine and midazolam groups (MIDEX trial) and 251 and 247 patients in the dexmedetomidine and propofol groups (PRODEX trial), respectively (Figure 1). Diagnostic groups and severity of organ failures20 at baseline were comparable between the treatment groups (Table 1). In the MIDEX trial, 53 midazolam patients (21.1%) and 68 dexmedetomidine patients (27.3%) died between randomization and follow-up at day 45 (P = .12). In the PRODEX trial, 48 propofol patients (19.4%) and 43 dexmedetomidine patients (17.1%) died during this period (P = .56).
Patients in MIDEX received less dexmedetomidine compared with patients in PRODEX (Table 2). Noninferiority of dexmedetomidine vs standard care was confirmed in both studies (time at target sedation without rescue medication: midazolam, 56.6%, vs dexmedetomidine, 60.7%; propofol, 64.7%, vs dexmedetomidine, 64.6%). The estimated ratio of dexmedetomidine vs midazolam in time at target sedation was 1.07 (95% CI, 0.97-1.18; P = .15), and of dexmedetomidine vs propofol, 1.00 (95% CI, 0.92-1.08; P = .97) (eFigure 1). For the intention-to-treat population, the estimated ratios were dexmedetomidine/midazolam, 1.09 (95% CI, 0.99-1.19) and dexmedetomidine/propofol, 0.97 (95% CI, 0.89-1.04). Dexmedetomidine patients had higher actual RASS scores in both studies (P < .001) (Table 2 and eTable 1).
Study drug discontinuation rates were similar in dexmedetomidine and standard care patients (midazolam, 50/250 [20%], vs dexmedetomidine, 60/249 [24%]; propofol, 58/247 [23%], vs dexmedetomidine, 71/251 [28%]), but discontinuation due to lack of efficacy was more frequent in dexmedetomidine patients (midazolam, 10/250 [4%], vs dexmedetomidine, 23/249 [9%]; P = .02; propofol, 13/247 [5%], vs dexmedetomidine, 36/251 [14%]; P < .001). Lack of efficacy within the first 24 hours was less frequent in the midazolam vs dexmedetomidine study (5 of 23 instances) than in the propofol vs dexmedetomidine study (15 of 36 instances).
The median duration of mechanical ventilation (including noninvasive ventilation) in MIDEX was 164 hours (IQR, 92-380 hours) for midazolam and 123 hours (IQR, 67-337 hours) for dexmedetomidine (Gehan-Wilcoxon P = .03). In PRODEX, it was 118 hours (IQR, 48-327 hours) for propofol and 97 hours (IQR, 45-257 hours) for dexmedetomidine (Gehan-Wilcoxon P = .24) (Figure 2). The median time to extubation in MIDEX was 147 hours (IQR, 81-325 hours) for midazolam and 101 hours (IQR, 65-313 hours) for dexmedetomidine (Gehan-Wilcoxon P = .01). In PRODEX, it was 93 hours (IQR, 45-286 hours) for propofol and 69 hours (IQR, 39-184 hours) for dexmedetomidine (Gehan-Wilcoxon P = .04) (eFigure 2 and 3).
The median length of stay in the ICU from randomization until the patient was medically fit for discharge was not significantly different in the 2 studies (midazolam, 243 hours [IQR, 140-630 hours], vs dexmedetomidine, 211 hours [IQR, 115-831 hours]; propofol, 185 hours [IQR, 93-520 hours], vs dexmedetomidine, 164 hours [90-480 hours]) (Figure 2). There were no significant differences between dexmedetomidine and standard care in length of hospital stay (eAppendix and eTables 2 through 9).
Patients receiving dexmedetomidine were more arousable, more cooperative, and better able to communicate their pain than patients receiving either midazolam or propofol (P ≤ .001 for each component separately and for total VAS score) (Table 3).
Sedation stops in the MIDEX trial were performed on 93.3% (midazolam) and 89.7% (dexmedetomidine) of eligible study days when no contraindication existed; in the PRODEX trial, sedation stops were performed on 90.1% (propofol) and 89.0% (dexmedetomidine) of days (Table 2). The most common reasons to restart sedation after a sedation stop were poor tolerance of the endotracheal tube or mechanical ventilation, agitation or anxiety, and cardiovascular instability (eTable 10). Changes in serum glucose over time were not different between treatments in any of the studies (eTable 11).
In the MIDEX trial, the adverse event hypotension was recorded in 29 of 250 midazolam patients (11.6%) vs 51 of 247 dexmedetomidine patients (20.6%) (P = .007). Bradycardia was reported in 13 of 250 midazolam patients (5.2%) and in 35 of 247 dexmedetomidine patients (14.2%) (P < .001). In the PRODEX trial, hypotension and bradycardia were reported at similar rates in both groups. First-degree atrioventricular block in MIDEX was observed in 3 patients in each group and, in PRODEX, in 2 propofol patients (0.8%) and 9 dexmedetomidine patients (3.7%) (P = .04). There were no differences between dexmedetomidine and standard care in infectious adverse events. Critical illness polyneuropathy was less common in patients receiving dexmedetomidine than in those receiving propofol (2 patients vs 11 patients, respectively; P = .02). (For detailed adverse and serious adverse events refer to the eAppendix and eTables 12 through 15.)
In the MIDEX trial, rates of neurocognitive adverse events through 48 hours of follow-up (agitation, anxiety, delirium, etc) were not different between midazolam and dexmedetomidine patients. In PRODEX, neurocognitive adverse events were reported in 71 of 247 propofol patients (29%) and in 45 of 251 dexmedetomidine patients (18%) (P = .008); also, dexmedetomidine patients received concomitant treatment for agitation, anxiety, and delirium less frequently (eTable 15). In both studies, there were no differences between the treatments in number of patients needing reinstitution of sedation due to agitation and anxiety or in delirium assessed using the Confusion Assessment Method for ICU Patients (CAM-ICU)21 at 48 hours after stopping study sedation. Serious adverse events were equally common between treatment groups in both studies.
These 2 trials demonstrated that dexmedetomidine was not inferior to midazolam or propofol for long-term sedation in mechanically ventilated ICU patients. Dexmedetomidine's noninferiority compared with these standard sedation strategies in mild to moderate sedation was confirmed. Dexmedetomidine appeared to shorten mechanical ventilation compared with midazolam but not compared with propofol; however, time to extubation was reduced compared with both midazolam and propofol. Dexmedetomidine enhanced patients' ability to communicate pain to the nursing staff, possibly contributing to the earlier extubation. Accordingly, dexmedetomidine may provide clinically relevant benefits compared with standard sedation, even when measures to reduce the risks of oversedation are implemented. The better arousability and ability to communicate pain should allow more appropriate use of opioids and facilitate earlier mobilization and functional recovery.
We observed in our pilot study16 that dexmedetomidine was not suitable for deep sedation. Therefore, these pivotal trials focused on light to moderate sedation. Despite this, the study treatment was discontinued due to lack of efficacy more frequently in dexmedetomidine patients in both trials. With the current maximum dose, lack of efficacy can be expected in approximately 1 in every 8 to 10 patients. Whether higher doses of dexmedetomidine could safely be used should be addressed in future studies. Dexmedetomidine doses were substantially lower in the midazolam vs dexmedetomidine than in the propofol vs dexmedetomidine study despite similar sedation levels. This was likely due to the remaining effect of preceding midazolam sedation.
Dexmedetomidine has been proposed to reduce the duration of mechanical ventilation.16,17 Others observed earlier extubation with dexmedetomidine when compared with midazolam.17 We observed that the difference between dexmedetomidine and midazolam in the proportion of mechanically ventilated patients changed over time and was not statistically significant in the primary analysis. Because median length of study drug infusion in the midazolam vs dexmedetomidine study was only 42 to 47 hours, any effect of dexmedetomidine would be expected early in a large proportion of patients. Furthermore, since the study drug was limited to 14 days, but mechanical ventilation was considered up to 45 days, standard care given after dexmedetomidine may have reduced any benefit from dexmedetomidine. Also, imputation of length of mechanical ventilation to 45 days in patients who died may have confounded early treatment effects. Accordingly, the alternative statistical analysis indicated significantly shorter mechanical ventilation with dexmedetomidine than midazolam and earlier extubation in both studies. If only observed data are included, mechanical ventilation is significantly shorter with dexmedetomidine in both trials (eTable 5). The present and previous trials suggest that dexmedetomidine shortens mechanical ventilation compared with benzodiazepine infusions, even when frequent monitoring of sedation and sedation stops are used.
This is the first large-scale study comparing dexmedetomidine with propofol in long-term sedation. Main advantages of propofol are short duration of action and rapid awakening when sedation is stopped,3,22 unless used long-term in high doses.13 Mechanical ventilation was shorter with propofol than lorazepam.22 Our results indicate that duration of mechanical ventilation is similar with dexmedetomidine and propofol, but dexmedetomidine favors earlier extubation.
All sedatives have cardiovascular adverse effects. As an α2-adrenoreceptor agonist, dexmedetomidine can cause bradycardia and hypotension. As in previous studies,16,17 bradycardia was more common with dexmedetomidine. Hypotension and cardiovascular instability other than bradycardia rarely necessitated stopping the study in all study groups, despite severe cardiovascular dysfunction (cardiovascular Sequential Organ Failure Assessment score >2) in more than 60% of patients at the baseline. The exclusion of patients with a specific risk of adverse effects with dexmedetomidine—those with bradycardia and atrioventricular block—may have introduced some bias favoring dexmedetomidine.
The 45-day mortality was higher in the MIDEX study than the PRODEX study (P = .03). This was mainly related to the difference in mortality between the groups receiving dexmedetomidine (27.3% in MIDEX vs 17.1% in PRODEX), whereas standard-care group mortalities were comparable (21.1% with midazolam vs 19.4% with propofol). When all dexmedetomidine patients were compared with all standard-care patients, mortality was similar (22.2% vs 20.3%, P = .49). This is consistent with the only previous large study comparing dexmedetomidine with midazolam in long-term sedation (30-day mortality, 25% for midazolam vs 23% for dexmedetomidine17). The only trial reporting 1-year mortality after dexmedetomidine sedation found no difference between dexmedetomidine and lorazepam.15
Delirium is common during prolonged intensive care,4,7,9,15,17 and sedation may be an independent risk factor.4 Dexmedetomidine reduced the composite end point of delirium and coma as compared with lorazepam without sedation stops,15 and delirium as compared with midazolam.17 Our pilot study suggested increased delirium with dexmedetomidine.16 In the present studies, incidence of neurocognitive disorders, including delirium, was similar with dexmedetomidine and midazolam, whereas dexmedetomidine was associated with fewer neurocognitive disorders than propofol. Others have found that dexmedetomidine sedation—in contrast to propofol—preserved or even improved cognitive function in patients with decreased baseline cognition.23 These seemingly conflicting results may be related to the definition of delirium. We used the reported adverse events and assessed delirium using CAM-ICU only once, 48 hours after stopping study drugs. We found more clinically apparent critical illness polyneuromyopathy in propofol patients; this observation is inconclusive and should be studied further.
The main strengths of these studies are the large sample size, proof of noninferiority in maintaining sedation, use of double dummy to avoid unmasking, and frequent sedation assessment and daily sedation stops. There are several limitations. The standard sedation preceding randomization may have masked benefits of dexmedetomidine during shorter exposure. A change of drug may have increased the lack of efficacy early during dexmedetomidine infusion, which was observed in the PRODEX study. Because of clinical contraindications, scheduled sedation stops were not always performed: the rates are similar or slightly higher than those reported by others.9 Spontaneous breathing trials were performed only in about half of the sedation stops, as compared with approximately 60% of those screened in the Awakening and Breathing Controlled trial.9 The lack of a usual care control group including bolus administration of midazolam could be considered a study limitation. However, published surveys24,25 and the usual care in study centers indicate that midazolam infusion is very common. Weaning from mechanical ventilation and criteria for extubation were not standardized. The large sample size and randomization should minimize bias induced by different weaning practices. The effects of the study drugs should be interpreted with the concomitant use of opiates and rescue medications and the target of light to moderate sedation; however, this corresponds to their clinical use. Finally, we assessed sedation from the caregiver's perspective. Future studies should include the patient's perspective of quality of sedation as well.
In summary, dexmedetomidine was noninferior to propofol and midazolam in maintaining the target sedation level in a broad spectrum of ICU patients requiring prolonged mechanical ventilation. Dexmedetomidine appeared to reduce the duration of mechanical ventilation as compared with midazolam, reduced the time to extubation as compared with both midazolam and propofol, reduced delirium as compared with propofol, and was associated with improved patient communication with the nursing staff but had no effect on length of ICU or hospital stay. Incidences of hypotension and bradycardia were higher with dexmedetomidine than with midazolam but comparable with propofol. We conclude that dexmedetomidine is feasible for long-term sedation in intensive care patients and may provide clinically relevant benefits by reducing the duration of invasive ventilation and improving comfort.
Corresponding Author: Jukka Takala, MD, PhD, Department of Intensive Care Medicine, Bern Univer sity Hospital, CH-3010 Bern, Switzerland (email@example.com).
Author Contributions: Drs Jakob and Ruokonen contributed equally as first authors. Drs Ruokonen, Jakob, and Takala had full access to the study data. Dr Takala had the final responsibility for the decision to submit the manuscript. Drs Jakob and Ruokonen served as co–principal investigators and, with Dr Takala, conceived the original idea of the 2 studies.
Study concept and design: Jakob, Ruokonen, Grounds, Sarapohja, Garratt, Pocock, Bratty, Takala.
Analysis and interpretation of data: Jakob, Ruokonen, Sarapohja, Garratt, Pocock, Bratty, Takala.
Drafting of the manuscript: Jakob, Ruokonen, Grounds, Sarapohja, Garratt, Pocock, Bratty, Takala.
Critical revision of the manuscript for important intellectual content: Jakob, Ruokonen, Grounds, Sarapohja, Garratt, Pocock, Bratty, Takala.
Statistical analysis: Jakob, Ruokonen, Sarapohja, Pocock, Takala.
Obtained funding: Jakob, Takala.
Administrative, technical, or material support: Ruokonen, Sarapohja, Garratt, Bratty.
Study supervision: Jakob, Ruokonen, Takala.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. This study was sponsored by Orion Pharma, Espoo, Finland, through research contracts negotiated directly with the participating hospitals. Orion Pharma, Orion Corporation, is the originator of dexmedetomidine. On behalf of Drs Jakob and Takala, a grant and consulting fees were paid to the Bern University Hospital Department of Intensive Care Medicine to cover the costs of performing the study. The department was reimbursed for the authors' travel costs to publication committee meetings. Dr Jakob served as an expert for preparing the regulatory filing of the drug; the money was also paid into a departmental fund. Additionally, the Department of Intensive Care Medicine has, or has had in the past, research contracts with Abbott Nutrition International, B. Braun Medical, CSEM, Edwards Lifesciences Services, Kenta Biotech, Maquet Critical Care, and Omnicare Clinical Research and research and development or consulting contracts with Edwards Lifesciences, Maquet Critical Care, and Néstle. The money is or was paid into a departmental fund; no author received any personal financial gain. The department has received unrestricted educational grants from the following organizations for organizing a quarterly postgraduate educational symposium, the Berner Forum for Intensive Care: Fresenius Kabi, MSD, Lilly, Baxter, Astellas, AstraZeneca, B. Braun, CSL Behring, Maquet, Novartis, Covidien, Mycomed, and RobaPharma. Dr Grounds received a consulting fee from Orion Pharma during planning and execution of the study. He and members of his clinical staff at St George's Hospital received monetary support from Orion for travel to study-related meetings to ensure compliance with the study protocol. His department received payment of a fee per patient recruited to the study, as well as drugs used in the study and support personnel to assist with data input. Dr Ruokonen's institution, Kuopio University, received a grant from Orion to carry out the study, as well as consulting fees and reimbursement of travel funds. Messrs Sarapohja, Garratt, and Bratty were full-time employees of Orion Pharma throughout the period of the project. Their routine travel expenses were reimbursed as part of their employment. Dr Pocock of the London School of Hygiene and Tropical Medicine received a consulting fee from Orion in connection with the study, and his institution received a grant. London School of Hygiene and Tropical Medicine also received a grant for independent statistical review performed by Dr Duolao Wang.
Funding/Support: This study was sponsored by Orion Pharma, Espoo, Finland, through research contracts negotiated directly with the participating hospitals.
Role of the Sponsors: The original idea was presented to the sponsor by Drs Jakob and Takala. The sponsor and the principal investigators designed the study and the statistical analysis plan. Data were collected by the investigators using the electronic data capture system provided by the sponsor. Data collection and quality control were managed by the contract research organization. The database was managed by the sponsor. Primary analysis according to the statistical analysis plan was performed by the statistician of the sponsor (Mr Sarapohja) and was also confirmed by Dr Duolao Wang under supervision of Dr Pocock. Data were interpreted by the publication committee with members from the sponsor company (Messrs Sarapohja, Garratt, and Bratty). Preparation, review, or approval of the manuscript was performed only through the coauthor members of the publication committee; according to the study contracts, the sponsor had the right to comment on the draft, but the publication committee had the final decision, and the decision to submit the manuscript was the responsibility of the senior author.
Independent Statistical Analysis: Analysis was undertaken by Dr Duolao Wang (Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, United Kingdom) under the supervision of Dr Pocock, Medical Statistics Department, London School of Hygiene and Tropical Medicine. Full access to all of the data used in the study was provided and an independent analysis of the primary and secondary end points reported in this article was performed by repeating the analyses and verifying P values and 95% confidence intervals. Consistency between the objectives set out in the protocol, the prespecified statistical analysis plan, and results of the statistical analysis produced by the sponsor was verified. No discrepancies were found. Drs Jakob, Ruokonen, and Takala also had full access to the data and performed the analyses independently from those of the sponsor. The results reported from these independent analyses were identical to those of the sponsor.
MIDEX Study Group Members: Belgium: Brussels: H. Spapen (UZ Brussel); J-L. Vincent (Université Libre de Bruxelles–Erasme University Hospital); Gent: K. Colpaert (Universitaer Ziekenhuis Gent); Liege: B. Lambermont (Department of Medicine, University Hospital of Liege). Estonia: Tallin: U. Kivistik (North Estonia Medical Centre Foundation); A. Saar (East Tallin Central Hospital); V. Toome (North Estonian Medical Centre); Tartu: K. Tamme (Tartu University Hospital). Finland: Tampere: J. Tenhunen (Tampere University Hospital); Oulu: T. Ala-Kokko (Oulu University Hospital). France: Paris: J-D. Chiche (Groupe Hospitalier Cochin); P. Montravers (Hôpital Bichat-Claude Bernard); Angers: A. Mercat (Centre Hospitalier Universitaire d’Angers); Argenteuil: H. Mentec (Centre Hospitalier Victor Dupouy); Grenoble: J-F. Timsit (Centre Hospitalier Universitaire de Grenoble); La Roche sur Yon: J. Reignier (Service de Réanimation, CHD Les Oudairies); Lille: F. Saulnier (Hôpital Albert Calmette); Limoges: A. Dugard (Centre Hospitalier Universitaire de Limoges); Orléans: T. Boulain (Centre Hospitalier Régional d’Orléans, Hôpital de La Source); Poitiers: R. Robert (Centre Hospitalier Universitaire de Poitiers); Tours: E. Mercier (Centre Hospitalier Régional et Universitaire–Hôpital Bretonneau). Germany: Bonn: C. Putensen (Universitätsklinikum Bonn); Greifswald: M. Grundling (Universitätsklinikum Greifswald); Tübingen: K. Unertl (Universitätsklinikum Tübingen). Netherlands: Zwolle: F. Snellen (Isala Klinieken); Amsterdam: A. Beishuizen (VU Medisch Centrum); Apeldoorn: P. Spronk (Gelre Hospital–Apeldoorn); Breda: B. van der Meer (Amphia Ziekenhuis); Dordrecht: A. Koopman-Van Gemert (Albert Schweitzer Hospital); Haarlem: N. Fennema (Kennemer Gasthuis); Tilburg: B. Speelberg (St Elisabeth Ziekenhuis); Venlo: N. Foudraine (Viecuri Medical Centre). Norway: Oslo: S. Walter and E. Helset (Ulleval University Hospital); R. Lovstad (Oslo University Hospital–Aker); A. Stubhaug (Oslo University Hospital, Rikshospitalet); Bergen: A. Guttormsen (Haukeland University Hospital). Switzerland: Bern: S. Jakob (Bern University Hospital [Inselspital] and University of Bern); Winterthur: A. Haller (Kantonsspital Winterthur); Zürich: M. Maggiorini (Universitätsspital Zürich). United Kingdom: Birmingham: G. Perkins (MIDRU, Heart of England NHS Foundation Trust); A. Whitehouse (Selly Oak Hospital); Plymouth: P. MacNaughton (Derriford Hospital).
PRODEX Study Group Members: Belgium: Aalst: I. Demeyer (Onze-Lieve-Vrouw, Ziekenhuis); Genk: R. de Jongh (Ziekenhuis Oost Limburg, Schiepse Bos); Gent: K. Colpaert (Universitaer Ziekenhuis Gent). Finland: Kuopio: I. Parviainen (Kuopio University Hospital); Espoo: T. Oksanen (HUCH, Jorvi Hospital); Helsinki: M. Kaukonen (HUCH, Meilahti Hospital); Joensuu: M. Reinikainen (North Karelia Central Hospital); Lahti: P. Loisa (Päïjät-Häme Central Hospital); Lappeenranta: S. Hovilehto (South Karelia Central Hospital); Seinäjoki: K. Saarinen (Seinäjoki Central Hospital); Tampere: J. Tenhunen (Tampere University Hospital). Germany: Berlin: C. Spies (Charité–Universitätsmedizin Berlin); Erlangen: J. Schuttler (Universitätsklinikum Erlangen); Frankfurt am Main: K. Zacharowski (Klinikum der J. W. Goethe-Universität); Giessen: T. Menges (University of Giessen and Marburg); Halle: J. Soukup (Universitätsklinikum Halle); Heidelberg: J. Motsch (Universitätsklinikum Heidelberg); Homburg/Saar: T. Volk (Universitätsklinikum des Saarlandes); Leipzig: U. Kaisers (University Leipzig, Medical Faculty); A. Sablotzki (Klinikum St Georg); Tübingen: K. Unertl (Universitätsklinikum Tübingen); Wetzlar: J. Engel (Klinikum-Wetzlar-Braunfels); Netherlands: Breda: B. van der Meer (Amphia Ziekenhuis); Hertogenbosch: F. Rozendaal (Jeroen Bosch Ziekenhuis); Hoorn: P. Knüpfer (Westfries Gasthuis); Tiel: M. van Iperen (Rivierenland Hospital). Russia: Kemerovo: E. Grigoryev (M. A. Podgorbunsky Municipal Clinical Hospital); Krasnodar: Zabolotskikh (Municipal Hospital No. 2, Krasnodar Diversified). Switzerland: Bern: S. Jakob (Bern University Hospital [Inselspital] and University of Bern). United Kingdom: London: R. Grounds (St George's Hospital); Bury St Edmunds: J. Cardy (West Suffolk Hospital NHS Trust); Edinburgh: T. Walsh (Edinburgh Royal Infirmary); Leeds: A. Mallick (Leeds General Infirmary); Livingston: L. Morrison (St John's Hospital).
Previous Presentation: The main results were presented orally at the 31st annual International Symposium on Intensive Care and Emergency Medicine (ISICEM); March 22-25, 2011; Brussels, Belgium.
Additional Contributions: We thank Jeannie Wurz, BA, a medical editor employed by the Department of Intensive Care Medicine at the Bern University Hospital, for editorial assistance. She did not receive compensation besides her salary.
Create a personal account or sign in to: